Evaluation of efficacy and toxicity in two different hypofractionated 3D-conformal external beam radiotherapy schedules in localised muscle invasive bladder cancer

Journal of B.U.ON.

Volumn 18, Issue 4, 2013, Pages 942-948

  Kouloulias, V ^a   Mosa, E ^a   Tolia, M ^a   Kantzou, I ^b   Koliarakis, N ^a   Platoni, K ^a   Georgakopoulos, I ^a   Siatelis, A ^c   Sarris, G ^c   Beli, I ^a   Chrisofos, M ^c   Kelekis, N ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b ANDREAS SYGROS HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bladder cancer; Hypofractionated radiotherapy; Radiobiology; Relapse free survival; Toxicity

Indexed keywords

ANTIDIARRHEAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; CYSTALGIA; CYSTECTOMY; DIARRHEA; DIET; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GASTROINTESTINAL TOXICITY; HEMATURIA; HUMAN; HUMAN TISSUE; MALE; MUSCLE INVASIVE BLADDER CANCER; NOCTURIA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECTAL IRRITATION; RECTAL PAIN; RECTUM HEMORRHAGE; RECURRENCE FREE SURVIVAL; URINARY FREQUENCY; URINARY URGENCY; VERY ELDERLY; VISUAL ANALOG SCALE;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84893111873     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. Ca Cancer J Clin 2010;60:277-300.
2. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
3. Howe HL, Wu X, Ries LA et al. Annual report to the nation on the status of cancer, 1975 - 2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711-1742. (Pubitemid 44582941)
4. Hagan MP, Winter KA, Kaufman DS et al. RTOG 97-06:Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelcrated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J rad Oncol Biol Phys 2003;57:665-672.
5. Gospodarowicz MK, Hawkins NV, Rawlings GA et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder:Failure analysis. J Urol 1989;42:1448-1453.
6. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavolt-age x-ray therapy. Radiother Oncol 1986;7:299-310. (Pubitemid 17232169)
7. Quilty PM, Kerr GR, Duncan W. Prognostic indices for bladder cancer:An analysis of patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage therapy. Radiother Oncol 1986;7:311-321.
8. National Comprehensive Cancer Network (NCCNTM) Guidelines v 1.2012 Bladder Cancer.
9. Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer:Long-term results. J Clin Oncol 2001;20:3061-3071.
10. Sauer R, Birkenhake S, Kuhn R et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998;40:121-127.
11. McLaren BD, Morrey D, Malcolm D, Mason MD. Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiother Oncol 1997;43:171-174. (Pubitemid 27261587)
12. Lydon A, Duchesne GM. How should we palliate bladder cancer? Clin Oncol 1992;4:273-274.
13. Zelefsky MJ, Kollmeier MM, Small EJ, Rosenberg JE. Cancer of the bladder, Ch 44, pp 642-645. In:Philips T, Hoppe R, Roach M:Leibel's Textbook of Radiation Oncology (3rd Edn). Elsevier-Saunders, Philadelphia, PA, 2010.
14. Munro NP, Sundaram SK, Weston PM et al. A 10-year retrospective review of a non randomized cohort of 458 patients undergoing radical radiotherapy or cys-tectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 2010;77:119-124.
15. Housset M. Maulard C, Chretien Y et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder:A prospective study. J Clin Oncol 1993;11:2150-2157.
16. Maciejiewski B, Majewski S.Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991;21:163-170.
17. DeNece W, Lybeert ML, Goor C et al. Radiotherapy for T2 and T3 carcinoma of the bladder:The influence of overall treatment time. Radiother Oncol 1995;36:183-188.
18. Fowler J. The linear quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-694. (Pubitemid 19194494)
19. TNM classification of malignant tumours. AJCC Cancer Staging Manual (7th Edn). Springer Science and Business Media, 2010.
20. Bayley AJ, Catton CN, Haycocks T et al. A randomized trial of supine vs. Prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. Radiother Oncol 2004;70:37-44. (Pubitemid 38177160)
21. ICRU 50.Prescribing, recording and reporting photon beam therapy. Bethesda, MD:ICRU;1993.
22. International Commission on Radiation Units and Measurements (ICRU).Report 62. Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU Report 50). Bethesda, MD:ICRU, 1999.
23. Marks LB, Yorke ED, Jackson A et al. Use of Normal Tissue Complication Probability Models in the Clinic. Int J Radiat Oncol Biol Phys 2010;6:S10-S19.
24. Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122.
25. Thames HD, Hendry JH (Eds):Fractionation in radiotherapy. Tayror & Francis, London, 1987.
26. Mazeron JJ, Scalliet P, Van Limbergen E, Lartigau E. Radiobiology of Brachytherapy and the Dose-Rate Effect, http://www.estro-education.org/ publications/ documents/e%204%20%2023072002%20radiobiol-ogy%20print-proc.pdf
27. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346.
28. Ohnhaus EE, Adler R. Methodological problems in the management of pain:A comparison between the verbal rating scale and the visual analogue score. Pain 1975;1:379-384.
29. Fowler JF. Review:total doses in fractionated radio-therapy:impiications of new radiobiological data. Int J Radiat Biol Relat Stud Phy Chem Med 1984;46:103-120. (Pubitemid 14067617)
30. Jose CC, Price A, Norman A et al. Hypofractionated Radiotherapy for Patients with Carcinoma of the Bladder. The Royal Marsden Hospital, Sutton, UK. Clin Oncol 1999;11:330-333.
31. Scholten AN, Leer JW, Collins CD, Wondergem J, Hermans J, Timothy A. Hypofractionated radiotherapy for invasive bladder cancer. Radiother Oncol 1997;43:163-169. (Pubitemid 27261586)
32. Kaufman DS, Winter KA, Shipley WU et al. The initial results in muscle-invading bladder cancer of RTOG 95-06:Phase I-II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluo-rouracil followed by selective preservation or cystectomy depending on the initial response. Oncologist 2000;5:471-476.
33. Pos FJ, van Tienhoven G, Hulshof MC et al. Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiother Oncol 2003;68:75-80. (Pubitemid 37289339)
34. Cowan RA, McBain CA, Ryder WD et al. Radiotherapy for muscle-invasive carcinoma of the bladder. Int J Radiat Oncol Biol Phys 2004;59:197-207.
35. Sengelov L, von der Maase H. Radiotherapy in bladder cancer. Radiother Oncol 1999;52:1-14. (Pubitemid 29461090)
36. Muren L, Redpath AT, McLaren D. Treatment margins and treatment fractionation in conformal radiotherapy of muscle-invading urinary bladder cancer. Radiother Oncol 2004;71:65-71. (Pubitemid 38452903)
37. Steel GG, Mc Millan Tj, Peacock JH. The 5Rs of radiobiology. Int J Radiat Oncol Biol Phys 1989;56:1054-1058.
38. Pos FJ, Hart G, Schneider C, Sminia P. Radical radiotherapy for invasive bladder cancer:What dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006;64:1168-1173.